SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SYNTHETECH - NZYM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (349)12/28/2000 11:47:25 AM
From: Dan Gibbs  Read Replies (1) of 372
 
Tuck,

Nateglinide, the Novartis diabetes drug that was approved last week, is a di-peptide-like molecule (N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine. I suspect we would already have clues if NZYM was working on this project (such as increased orders for launch quantities of drug), but it is a good example of the type of small molecule, peptide-like drugs that NZYM will (hopefully) be involved with in the next few years.

Dan
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News